Tumour Microenvironment

Tumour Microenvironment encompasses the complex cellular and acellular components surrounding cancer cells including stromal cells, immune cells, blood vessels, extracellular matrix, and signalling molecules that collectively influence tumour growth, progression, metastasis, and therapeutic responses. This dynamic ecosystem comprises cancer-associated fibroblasts, diverse immune populations exhibiting pro-tumour or anti-tumour activities, endothelial cells forming vasculature, and numerous cytokines and chemokines creating biochemical landscapes affecting cellular behaviours.

The biopharmaceutical industry increasingly targets tumour microenvironment components developing therapies modulating stromal cells, normalising vasculature, reshaping immune landscapes, or disrupting supportive interactions. Immunotherapy success depends heavily on microenvironment composition, with immune checkpoint inhibitors proving most effective in inflamed tumours containing T cells. Combination strategies address multiple microenvironment components simultaneously, enhancing drug delivery through vascular normalisation, depleting immunosuppressive cells, or activating immune effectors. Research employs sophisticated models including patient-derived organoids and humanised mouse systems. Single-cell technologies reveal microenvironment heterogeneity across patients and tumour types. Spatial transcriptomics maps molecular features maintaining tissue architecture. Challenges include microenvironment heterogeneity between and within tumours and dynamic changes during treatment. As understanding deepens regarding microenvironment roles in disease progression and resistance, and therapeutic strategies evolve to target supportive elements, tumour microenvironment research continues revealing opportunities for improved treatments.